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Abstract: Background: Autism spectrum disorder (ASD) is a neurodevelopmental issue that 
disrupts behavior, nonverbal communication, and social interaction, impacting all aspects of an 
individual’s social development. The underlying origin of autism is unclear, however, oxidative 
stress, as well as serotonergic, adrenergic and dopaminergic systems are thought to be implicated 
in ASD. Despite the fact that there is no effective medication for autism, current pharmacological 
treatments are utilized to ameliorate some of the symptoms such as selfmutilation, aggression, 
repetitive and stereotyped behaviors, inattention, hyperactivity, and sleep disorders.   
Methods: In accord with the literature regarding the activity of herbal medicines on 
neurotransmitter function, we aimed to review the most worthy medicinal herbs possessing 
neuroprotective effects.   
Results: Based on the outcome, medicinal herbs such as Zingiber officinale, Astragalus 
membranaceu, Ginkgo biloba, Centella asiatica and Acorus calamus, have antioxidant activity, 
which can influence neurotransmitter systems and are potentially neuroprotective.   
Conclusion: Consequently, these herbs, in theory at least, appear to be suitable candidates within 
an overall management strategy for those on the autism spectrum.      
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1. INTRODUCTION 
Autism is a neurodevelopmental disorder characterized by deficits in social communication and 
interaction. It can be termed autism spectrum disorder (ASD) such that symptoms are classified 
into various types and degrees. Signs of autism commonly appear in infants of two or three years 
of age and certain developmental impediments may occur even earlier. Children suffering from 
ASD display different attitudes and emotions compared to subjects of comparable age and it is a 
lifelong developmental disorder. However, early intervention may subsequently lead to improved 
outcome and an educational program at a young age may well help individuals to have a 
moderately productive life with their own choices (1).  
 
Although the etiology of autism has remained unknown, environmental and genetic factors can 
modify the condition in terms of symptoms and severity. In extreme cases, autistic individuals 
become isolated and neglected and some clinical psychologists believe that cognitive impairment 
augments any deficiency in social skills. The primary problem resides in executive performance 
leading to insufficiencies in problem solving and action planning impeding their attention. All 
these deficits have a negative impact on the ability of individuals to function properly in social 
activities. Secondly, it has been suggested that people on the autism spectrum are not able to 
understand typical states of mind, so they cannot recognize and predict the intentions of others  
(2, 3). 
 
The prevalence rate of autism varies in different cultures and ethnic groups. It has been estimated 
for instance in the USA, that one out of every sixty-eight  children (~1.5%) are on the autism 
spectrum although an incidence of six per thousand (0.6%) has also been indicated. What is 
more, the ASD prevalence rate differs by gender and boys are thought to be affected 4.2 times 
more than girls. However, female subjects tend to have greater cognitive impairment and show 
more atypical behaviors. Such differences in occurrence frequency probably result from a 
disparity in symptom expression (4-6). The problem of managing ASD is that individuals are 
invariably focused on a confined number of objects and events. Many have considerable 
communication problems, and constantly need support. Therapeutic interventions are usually 
limited to behavioral and drug therapies and most behavioral training programs try to create self-
help, social and communication skills. Drug treatment is aimed at reducing and controlling 
problematic behaviors such as isolation, aggression and self-harm. Antiepileptic drugs are widely 
employed for ASD to reduce repetitive and stereotypical behaviors, social isolation and 
aggression as well as difficult behaviors such as hyperactivity, severe bitterness, mood swings 
and self-harm. However, some children do not respond positively to these drugs (7-11) and 
investigations have indicated both positive and negative effects of certain foods or plants, like 
Gingko, especially in combination with conventional treatments. The present review therefore 
aims to present herbal medicines that alleviate the signs and symptoms of autism highlighting 
their possible mechanisms (11). 
 
2. AUTISM PATHOPHYSIOLOGY 
 
The cause of autism has remained unknown, but ASD may occur concomitantly to several other 
genetic disorders. The characteristics of autism are clearly associated with a number of 
chromosomal aberrations, such as chromosomal proliferation, chromosomal removal, and 
reversal of chromosomes. Nonetheless, chromosomal abnormalities account for only 10% of 
cases of ASD. Transmission of autism symptoms is not attributable to just one gene alone, but it 
is more likely that it is a complex condition to which 15 different genes contribute. There is also 
a family relationship between autism disorder and other psychological problems. Evidence 
suggests that social, linguistic and psychological problems in autism disorders usually have a 
family background. Pregnancy and childbirth problems have been identified as important non-
genetic factors for the development of ASD. Consumption of drugs such as thalidomide and 
valproate during pregnancy as well as bleeding after the first trimester are chief environmental 
factors for autism development. Autopsy and fMRI analysis have provided insights into the 
relationship between autism and brain abnormalities. Post-mortem autopsies upon individuals on 
the autism spectrum have revealed that there are abnormalities in some parts of the brain such as 
the cerebellum and limbic system. Cerebellar abnormalities are related to movement 
impairments, including a lack of balance, manual skill defects and problems in hand movements. 
In addition, autopsy studies indicate that brain size in autism has a tendency to be larger than 
normal and such malformations initially occur during embryonic development (12-17). 
3. NUTRITION AND AUTISM  
 
Nutritional factors, especially micronutrients are essentially involved in neurogenesis (18) and  
medications are used to improve symptoms of autism including hyperactivity, irritability, 
attention problems, aggression, repetitive behavior, anxiety and depression. It has also been 
demonstrated that vitamins B6 and B12, magnesium and selenium are additionally beneficial in 
ASD. In view of this, it is recommended that individuals on the autistic spectrum should eat 
magnesium rich foods such as soybeans, spinach, almonds, pumpkin seeds, sunflower seeds, 
lentils, barley and broccoli. Furthermore, the consumption of cereals and brans can provide B 
group vitamins. Many studies have confirmed the positive effects of the Gingko plant by 
boosting memory and cognitive function while milk casein, gluten in certain foods and pasta 
exacerbate the symptoms of the condition. Likewise, canned and cooked foods, chocolate, 
artificial dyes and fast foods are also detrimental (3, 4). Acupuncture has been shown to possess 
value in ASD and physical exercise, as well as massage are of help. It has been reported that the 
levels of zinc, selenium, magnesium, vitamins A, B, C, D, E and carnitine (19, 20), are lower 
than normal in the blood and hair of children on the autism spectrum. Moreover, low levels of 
vitamin D (21) and folic acid (22) during pregnancy are major risk factors for the development of 
autism. In consequence, such outcomes emphasize the significant part nutrients play in ASD. In 
this regard, a double-blind trial disclosed a substantial improvement of symptoms in 3–12 year 
old children exhibiting autism (23). Another study on 3–8 year old autistic children receiving 
mineral supplements and multi-vitamins divulged improvements in receptive language and 
general behavior (24). In other conditions such as attention deficit hyperactivity disorder 
(ADHD) in children, vitamin B6 and magnesium also improves hyperactivity and 
hyperemotivity/aggressiveness accentuating the therapeutic usefulness of an Mg-B6 regimen 
(25).  
 
The composition and level of plasma and red blood cell fatty acids, particularly the concentration 
of omega-3 fatty acids (26), is essential to neural development. Therefore, consumption of fatty 
acids may be beneficial in ASD. In this regard, women who consumed higher levels of 
polyunsaturated fatty acids (PUFA) during pregnancy had a reduced risk of having children with 
autism in comparison to those with a lower PUFA intake. Additionally, the results of another 
study showed that consumption of omega-3 fatty acids (1.0 g daily) in 7–18 year old autistic 
children, significantly improved attention problems and core symptoms of their autism (27).  
 
 
4. AUTISM AND NEUROTRANSMITTER SYSTEMS 
Results of research support the assumption that autism disrupts synaptogenesis, and a number of 
neurotransmitter pathways may also play a part in susceptibility to autism. In this respect, based 
on various pathophysiological and genetic findings, neurotransmitter mechanisms and 
neurotrophic factors have been suggested as being involved in ASD. Serotonin and dopamine are 
monoamine neurotransmitters engaged in the modulation of adult cortical plasticity and are 
believed to play a vital role in the growth of the early cortex by controlling, migration and 
neuronal diversity. Serotonin functions through seven known receptor families (5-HT1 – 5-HT7) 
and is associated with homeostasis of sleep, emotions, awareness, learning, muscle mobilization, 
and endocrine functions. Dopamine operates via five receptor types (D1 – D5) and modifies 
various cognitive functions including reward, motivation, memory, awareness as well as problem 
solving and it is also critical in the control of voluntary movement. The metabolism of these two 
neurotransmitters is both complex and tissue-specific. In central neurons, serotonin is 
biosynthesized from tryptophan precursor in sequence by tryptophan hydroxylase then aromatic 
acid decarboxylase enzymes but it is catabolized by monoamine oxidase A (MAO-A). In 
contrast, dopamine is sequentially biosynthesized from tyrosine precursor by tyrosine 
hydroxylase then DOPA decarboxylase enzymes and it is subsequently broken down by both 
monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT). 
The outcome of extensive research indicates that both serotonergic and dopaminergic systems 
can be regarded as powerful candidate mechanisms involved in autism. Firstly, high blood and 
urine serotonin concentrations have been reported in roughly one-third of persons with autism, 
while normal peripheral dopamine levels have been recorded in ASD. Secondly, selective 
serotonin reuptake inhibitors (SSRIs) and dopamine receptor antagonists are inclined to diminish 
autism-related symptoms which include aggression, self-injury, and maladaptive behavior. 
Thirdly, positron emission tomography (PET) neuroimaging studies have unveiled an atypical 
serotonin synthesis imbalance in frontal, temporal and parietal cortices in autism. Moreover, 
dopaminergic activity appears to be changed in the anterior, medial, and prefrontal cortical 
regions in subjects with autism (28-31). In addition, studies have shown that other systems such 
as adrenergic, cholinergic and opioid neurotransmitter pathways plus glucocorticoids as well as 
amino acid neurotransmitters can participate in the pathophysiology of autism. Noradrenaline 
itself does not appear to be a participant initiating the signs of ASD. However, α-2 adrenoceptor 
agonists such as clonidine which reduce noradrenaline function, are capable of  managing 
hyperactivity in young persons with autism and yet these drugs have no effect on the core 
symptoms. β-adrenoceptor blockers on the other hand, are effective in controlling aggression, 
self-mutilation, and febricity (32).  In regard to the cholinergic system, a substantial reduction in 
muscarinic receptors in the cerebral cortex and a nicotinic receptor deficit has been recorded in 
the post-mortem brains of individuals with autism. Nevertheless, it is not evident how these 
variations relate to the causes of autism though the reduced effectiveness of nicotinic receptors 
might suggest that medicinal products with nicotinic agonist activity would boost attention (33). 
5. OXIDATIVE STRESS AND AUTISM   
Autism is associated with oxidative stress which is linked with excitotoxicity, impaired energy 
metabolism, inflammation, membrane lipid abnormalities and aberrant immune response. The 
markers of lipid peroxidation are increased in autism, indicating that oxidative stress (OS) might 
be associated with autism. The level of OS is evaluated by measuring the products of lipid 
peroxidation, glutathione and other antioxidants which act against reactive oxygen species 
(ROS). Also, membrane phospholipids, which are considered as prime targets for ROS, are 
usually altered in autism. In comparison to unaffected siblings, phosphatidylserine level in 
erythrocyte membrane of autism children is increased and phosphatidylethanolamine level is 
decreased. Antioxidant enzymes or their activities including glutathione peroxidase, superoxide 
dismutase and catalase in autism patients are decreased. Moreover, in autism, genetic and 
environmental factors may enhance the vulnerability to oxidative stress. These findings suggest 
the involvement of oxidative stress in the development of autism. Therefore, medicinal plants 
with antioxidant activity might be beneficial in these patients [34]. 
 
6. AUTISM AND MEDICINAL PLANTS  
Herbal medicines have been studied and yielded  encouraging outcomes in the therapy of a broad 
range of health complications involving cardiovascular and neurological issues (35, 36) in 
addition to diabetes mellitus (37, 38). These types of treatment can have reduced side effects and 
may even decrease the side effects of other agents such as gentamicin (39). Diagnosis of ASD is 
difficult since there is no widely available medical test and it is largely dependent on behavioral 
assessment and identification of developmental delay. There is an ancient Chinese term in which 
a condition could conceivably be equated with modern-day autism and it was defined as "Phlegm 
in the heart orifice”. During ancient times, there were not only alternative herbal treatments 
available, but also acupuncture was freely used, although even nowadays,   medicinal plant 
therapeutic mechanisms are often unclear and potential toxicity is an ever-present problem (40). 
Unfortunately, the number of studies intended to evaluate the activity of medicinal plants on 
autism is scarce. In respect of this,  herbal medicines with neuroprotective effects have potential 
as remedies for treating the signs of autism (41). The most noteworthy of these remedies are 
outlined below. 
 
7. ZINGIBER OFFINIALE 
Zingiber officinale (Ginger), which contains gingerol, paradols and shogaol, belongs to the 
Zingiberaceae family. It has been established that consumption of Z. officinale has antioxidant 
activity, an acetylcholinesterase inhibitory effect (AChEI), and neuroprotective as well as 
memory-enhancing properties. It is traditionally used to reduce the signs of autism and it is the 
plant root that is utilized for its neuroprotective capacity on ASD (42). In an experimental rodent 
model of age-related dementia, Z. officinale disclosed efficacy in enhancing  memory and 
increasing hippocampal neuronal density (43). Equally, in rats with focal cerebral ischemia, Z. 
officinale decreased brain infarct volume after unilateral middle cerebral artery occlusion and it 
induced a cognitive improvement which was partly ascribable to an antioxidant action  (44).  
Significant antioxidant effects of a 6-gingerol-rich fraction of Z. officinale and a protective action 
against the cerebral cortical damage induced by the neurotoxin acrylonitrile have been reported. 
Hence, this component of the plant extract counteracted the depletion of central glutathione as 
well as the activities of glutathione peroxidase (GPX), glutathione S-transferase (GST) and 
superoxide dismutase (SOD) caused by acrylonitrile. It also reestablished levels of nitric oxide, 
malondialdehyde (MDA) and the pro-inflammatory cytokines interleukin-6 (IL-6) and tumour 
necrosis factor-α (TNF-α) which were raised by the neurotoxin  (45). 
 
8. ASTRAGALUS MEMBRANACEUS 
Astragalus belongs to the legume family Fabacae and is frequently known as milkvetch. It has 
two commonplace species (Astragalus membranaceus and Astragalus mongholicus), which have 
been used in Eastern traditional medicine for many years. Astragalus membranaceus contains 
cycloartane-type triterpene glycosides that are utilized for their anti-inﬂammatory-, antioxidant- 
cardioprotective- and immune system stimulating activities. A. membranaceus has been used as 
an herbal remedy to treat general weakness as well as chronic illness, and to increase overall 
vitality. An extract of the other  common species, Astragalus mongholicus, has been shown in 
moderate doses, to possess anticonvulsant properties in a rodent model and may be beneficial in 
convulsive disorders (46). 
The A. membranaceus plant elevates the resistance of dopaminergic neurons to neurotoxins. As a 
consequence, in a Parkinson’s disease primary nigral cell culture model, the neurotoxin 6-
hydroxydopamine gradually becomes neutral following pretreatment with astragaloside IV 
extracted from the A. membranaceus root (47). In addition to this, the polysaccharide astragalan, 
present in A. membranaceus, is capable of attenuating aging and proteotoxic stress pathways by 
reducing aggregation-prone proteins and a global disruption of proteostasis (48).  
In peripheral nerve studies in rats, concentrations of astragaloside evoked a higher rate of sciatic 
nerve regeneration, improved numbers of myelinated axon growths plus greater evoked action 
potentials than corresponding controls. This activity was subject to a biphasic concentration-
effect relationship since there was a completely opposite effect which terminated nerve 
anastomosis at a higher concentration (49). In a later investigation, an aqueous extract of A. 
membranaceus was reported to augment a nerve growth factor promoted outgrowth of neurites in 
PC12 cells and this was further evidence for the regenerative and growth enhancing neuronal 
activity of  A. membranaceus (50). Once again, it would appear that it is the neuroprotective 
propensity present in the commonly employed aerial parts of the plant that contributes to its 
utility in traditional medicine (42) 
 
9. CENTELLA ASIATICA 
Centella asiatica (CA) is a traditional medicinal herb that belongs to the Apiaceae family and it 
is known as Pegaga in Malaysia or Goto kola in traditional Chinese and Ayurvedic medicine. C. 
asiatica grows in tropical swampy areas in many regions of the world but is native to India, 
China, Sri Lanka, Madagascar, Indonesia and Malaysia. The therapeutic  activity of C. asiatica is 
clearly related to a wide range of active constituents including pentacyclic triterpene derivatives, 
polyphenols, alkaloids, glycosides and flavonoids  (51). Over thousands of years, it has been 
extensively used in folk medicine; and currently, it has been incorporated into modern medicine 
for its antitubercular, antileprotic, memory enhancing, antitumor and wound healing 
characteristics (52). Tiwari et al., reported that due to its cholinergic, antioxidant and anti-
neuroinflammatory activities, there was a significant improvement in elderly patients with mild 
cognitive impairment arising from 6-month administration of C. asiatica (53). There are an 
increasing number of studies focusing on the neuroregenerative and brain supporting capacities 
of C. asiatica. Gray et al., described a positive effect of an aqueous C. asiatica extract which 
raised the expression of Synaptophysin and PSD95 synaptic markers in the hippocampus and 
frontal cortex of old and young mice (54). Synaptophysin and PSD95 are pre- and post-synaptic 
markers of spine density known as a structural basis for changes in cognition. 
C. asiatica has also been used to treat Alzheimer’s disease (AD) which is characterized by a 
decline in cognitive function. There are two hypotheses underlying the development of 
Alzheimer’s disease. Firstly, there is thought to be a cognitive decline due to the degeneration of 
cholinergic neurons. Secondly, neuronal damage occurs due to the generation of neurotoxic Aβ 
peptide oligomers and fibrils which are associated with inflammation and oxidative stress 
leading to neuronal dysfunction ultimately followed by the central deposition of amyloid 
plaques. Ramesh et al., found that C. asiatica aqueous leaf extract did not inhibit Aβ peptide 
aggregation nor did it bring about the disintegration of preformed fibrils. Therefore, it was 
speculated that apart from its antioxidant and anti-inflammatory properties, C. asiatica may act 
either by promoting α-secretase non-amyliodogenic processing of amyloid precursor protein 
(APP), or by inhibiting β-secretase (BACE1) thus preventing APP cleavage extracellularly and 
any subsequent formation of Aβ peptide (55). It has been demonstrated in vitro, that the 
triterpenoid saponin asiaticoside found in C. asiatica inhibits the phospholipase A2 (PLA2) 
subtypes cPLA2 and sPLA2 in cortical neurons. In light of this, stimulation of PLA2 activity is 
crucial to the neurotoxicity of Aβ peptide which leads to apoptosis and neuronal death, so the 
medicinal plant and its constituents have been proposed as a potential treatment for 
neurodegenerative conditions (56). Since mitochondrial dysfunction and oxidative stress are 
associated with cognitive impairment, Gray and coworkers studied the activity of C. asiatica on 
these fundamental pathways. In essence, C. asiatica improved cognitive function and elicited an 
expression of several electron transport chain (ETC) genes in the hippocampus, frontal cortex, 
cerebellum and liver of both young and aged mice. The changes in gene expression were 
considered to be an action on mitochondrial biogenesis and in combination with stimulated 
antioxidant response genes, this might have been an underlying factor in the observed 
improvement in cognition (54). 
Parkinson’s disease has a molecular basis centered around mitochondrial dysfunction and 
oxidative stress characterized by loss of motor control due to disrupted central 
neurotransmission. In relation to this, C. asiatica counteracted 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) neurotoxin-induced Parkinsonian-like oxidative stress biomarker 
accumulation (lipid hydroperoxides, xanthine oxidase and protein carbonyl content) in rat corpus 
striatum and hippocampus. Similarly, C. asiatica extensively reversed a concurrent MPTP-
incited decline in striatal and hippocampal total antioxidants, catalase, glutathione peroxidase 
and superoxide dismutase) (57). It was suggested therefore, that C. asiatica may well be an 
efficacious neuroprotective agent against neurodegenerative conditions typified by Parkinson’s 
disease (57). Analogously, asiaticoside isolated from C. asiatica maintained dopamine metabolic 
balance by antagonizing MPTP-induced neurotoxicity to ameliorate motor dysfunction and 
manifest both neuroprotective and antioxidant properties (58).  
Amongst a variety of  active compounds in C. asiatica, asiatic acid (AA) not only hastens 
neuronal regeneration but also stimulates elongation of neurites (59). Likewise, there is evidence 
in favor of a protective capability of asiatic acid against C(2)-ceramide-induced cell death by 
antagonizing apoptosis that is contingent upon mitochondria (60). Besides asiatic acid, phenolic 
compounds in C. asiatica have been proposed to retain a distinct therapeutic potential for 
Alzheimer’s disease treatment (61). Correspondingly, although C. asiatica lacked protective 
activity from oxidative damage and glutamate toxicity, administration of its aqueous extract in 
the Tg2576 AD transgenic Aβ peptide overexpressing mouse model ameliorated behavioral 
abnormalities associated with raised Aβ levels. In this instance, two major triterpene saponosides 
(madecassic acid plus asiatic acid mentioned above) and their heterosides; (asiaticoside and 
madecassoside) account for some of the positive effects of C. asiatica on the central nervous 
system. Also in AD, there is a cholinergic deficit particularly in nucleus basalis of Meynert 
neurons and choline acetyl transferase activity is diminished leading to the biosynthetic 
deficiency of acetyl choline which correlates with impaired memory (62).  
Acetylcholinesterase (AChE) hydrolyzes acetylcholine (ACh) i.e. its breakdown, so inhibition of 
AChE and the pseudocholinesterase enzyme butyrylcholinesterase (BChE), has been considered 
a potential target in drug development against AD and autism. Four inhibitors of AChE have 
been approved in AD treatment, namely, rivastigmine, tacrine, donepezil and galantamine which 
also stimulates nicotinic cholinergic receptors further increasing Ach release (63). Studies on 
these medications have divulged a potential usefulness for treating core and attendant ASD 
symptoms and further clinical trials have been advocated to substantiate their effectiveness in 
this respect (63). In the perspective of this outcome deduction, a hydroalcoholic extract of C. 
asiatica  has a definite inhibitory effect on AChE activity in vitro (64). Further evidence 
supporting a positive action of C. asiatica in persons with autism derives from the finding that a 
flavonoid mixture of luteolin, quercetin and rutin, all of which are also present in C. asiatica (65, 
66), has been shown to cause speech resumption in a trial with pediatric ASD participants (67).  
 
Glutamic acid decarboxylase (GAD) is a rate limiting enzyme that converts glutamate to the 
central neurotransmitter gamma amino butyric acid (GABA). In postmortem autistic cerebellar 
and parietal cortices, GAD protein has been shown to be appreciably reduced and this may be 
attributable to aberrations in levels of glutamate/GABA or the density of central GABA 
transporters or its receptors in autism (68). The possible influence of C. asiatica on GABA 
biosynthesis has been studied and an extract of the medicinal plant actually enhanced glutamic 
acid decarboxylase (GAD) activity (69). It may be hypothesized therefore, that any reversal of 
ASD symptoms by C. asiatica may be ascribed at least in part to a rise in GAD activity.  
To unravel the underlying mechanisms mediating C. asiatica actions, the MEP/ERK signaling 
pathway was regarded to be involved (59). In support of this, a neuritogenic effect of a 
standardised extract of C. asiatica (known as ECa 233) (70) has been shown to be mediated via 
ERK1/2 and Akt signaling pathways. Tyrosine kinase receptor activation triggers these 
molecular signals and several neurotrophic ligands such as nerve growth factor (NGF), brain 
derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) have been identified. Hence, 
activation of MEK/ERK and PI/2K/Akt increases cell survival, neuronal growth and 
differentiation (71). There is evidence that the ERK/RSK signaling pathway is a mediator of C. 
asiatica in terms of its memory enhancing property. Essentially, C. asiatica was found to 
increase phosphorylation of cAMP response element-binding protein (CREB) in neuroblastoma 
cells expressing Aβ1-42 (72). In a later study, an ethanolic extract of C. asiatica was reported to 
operate through the caspase-9 pathway (73). Indeed, treatment of l-buthionine-(S,R)-sulfoximine 
(BSO)-induced human neuron cell death with an ethanolic extract of C. asiatica, protected the 
neuronal cells against oxidative stress.  
 10. ACORUS CALAMUS 
Acorus calamus, known as “sweet flag” or “calamus” is a semiaquatic, perennial, aromatic herb 
from the Acoraceae family which is abundant in subtropical swampy or marshy habitats of Asia, 
North America, and Europe. The essential oil contained in the leaves and rhizomes of A. calamus 
have a range of biological activities that have been exploited in the treatment of various disease 
states. It is also used as rejuvenator for the brain and nervous system (74). 
Several antiepileptic drugs exhibit analgesic clinical effectiveness against neuropathic pain. In 
the case of the frequently adopted pentylenetetrazole (PTZ)-induced rodent convulsion model for 
epilepsy, there are thought to be two underlying mechanisms involved.   Primarily, convulsions 
induced by PTZ are regarded as being mediated through inhibition of gamma amino butyric acid 
(GABA) pathways in the CNS, or secondly, by increasing central noradrenergic activity. In 
regard to these assumptions, Jayaraman et al., reported an increase in onset latency and a 
reduction in PTZ-induced seizure duration in response to administration of A. calamus root. This 
outcome was rationally ascribed to a possible involvement of GABA-ergic or noradrenergic 
pathways in the activity of the herb (75). 
During pathological conditions, oxidative stress and neuroinflammatory processes contribute to 
behavioral and memory impairment. Recently, Esfandiari et al., reported that A. calamus was 
dose-dependently effective in preventing inflammation in a lipopolysaccharide (LPS) model of 
neuroinflammation which may subsequently augment Aβ peptide production and tau protein 
phosphorylation. The highest dose of an A. calamus aqueous fractional extract (600 mg/kg) 
demonstrated the most improved performance in a passive avoidance memory test as well as the 
lowest stress level in the elevated plus maze model. In addition, oxidative stress markers 
including superoxide dismutase, glutathione peroxidase and total antioxidant activity in 
hippocampal samples of A. calamus-treated cells were decreased along with lower 
malondialdehyde (MDA) levels compared to controls (76).  
 
Since Aβ peptide stimulates neuronal apoptosis in the brain and primary neuronal cultures, Geng 
et al., studied the activity of β-asarone, an important chemical constituent of the acoraceae 
family, on cognitive function and neuronal apoptosis in Aβ-hippocampally injected rats. The 
results showed that Aβ1-42-induced neuronal apoptosis in the hippocampus was hindered by β-
asarone through up-regulation of Bcl-2, Bcl-w, caspase-3 activation, and JNK phosphorylation 
(77). β-asarone exhibits suppressive activity on pro-inflammatory mediators via NF-κB signaling 
and the JNK pathway in activated microglial cells. It also prevents an LPS-induced increase in 
JNK phosphorylation in a concentration dependent manner. Inhibition of JNK reduces LPS-
provoked activity of COX-2, TNF-α and IL-6, which are key cytokines in cerebral inflammation 
and neurodegeneration. Since COX-2 is the effector of JNK-mediated neurotoxic degeneration of 
dopaminergic neurons, β-asarone may represent a putative therapy against neuroinflammatory 
disease (78).  
 
The inhibitory effect of a hydroethanolic extract of A. calamus rhizome on oxidative stress-
induced changes is achieved by clearing free radicals and upgrading the levels of antioxidant. 
Thus, increased striatal glutathione (GSH) content and glutathione-S-transferase (GST) activity 
along with decreased dopamine receptor density, suggests that the neurotoxic behavioural 
changes produced by acrylamide may be prevented following administration of A. calamus (79). 
It has also been reported that A. calamus extract mediates neuroprotection by reducing lipid 
peroxidation, glutathione levels and superoxide dismutase (SOD) activity after middle cerebral 
artery occlusion-induced ischaemia in rats (80). It is a combination of such antioxidant, 
neuroprotective and neurotransmitter function modifying activities of A. calamus that underlies 
its traditional use in individuals on the autism spectrum (42). 
 
11. GINKGO BILOBA 
Ginkgo biloba extract is a remedy that has presented promising outcomes in treating a wide 
variety of circulatory, brain and nerve health problems. The most common studies concerning G. 
biloba on neurological issues have focused on memory enhancement, arterial dementia, 
Alzheimer's disease and behavioral disorders. Use of G. biloba alongside psychiatric drugs either 
tends to strengthen their effect or decrease their side effects (81, 82). Flavonoids and terpenoids 
with antioxidant, anti-inflammatory and neuroprotective effects are the primary therapeutic 
constituent elements of G. biloba extract. Ginkgo also has beneficial effects on cognitive and 
neurological performance and this stems from antioxidant activity, arterial regulation, and 
platelet-activating factor antagonism to protect the brain from ischemic damage. G. biloba 
extract can modify several central nervous system and neurotransmitter functions. In accord with 
this, oral administration of G. biloba extract in rats has been shown to evoke an initial decrease 
in the concentration of the noradrenaline metabolite normetanephrine in the cerebral cortex. 
Subsequently, this initial effect was superseded by a raised normetanephrine level that was 
apparent up to two weeks later. This longer term G. biloba treatment however, led not only to a 
reduced cortical β-adrenoceptor density but also diminished β-adrenoceptor-stimulated adenylate 
cyclase activity (83). A later investigation corroborated the decrease in β-adrenoceptors in the 
frontal cortex as well as the hippocampus in response to 7-day oral treatment with extract of G. 
biloba (84). The findings of both of these studies were thought to signify an important β-
adrenergic system involvement in the therapeutic activity of G. biloba on learning and memory. 
In  an investigation using a  mouse model (85), an extract of G. biloba (EGb 761) was described 
as having a protective effect against MPTP-induced nigrostriatal dopaminergic neurotoxicity and 
it was deduced that inhibition of monoamine oxidase in the brain may have been responsible for 
this neuroprotective outcome (85). Likewise, in another study, the striatal dopaminergic 
neurotoxicity of MPTP delivered subcutaneously by osmotic minipumps was inhibited by 17-day 
dosing with G. biloba extract. It was highly noteworthy that this inhibitory counteractive 
response was independent of neurotoxic MPTP uptake by dopamine neurons (86). 
Bilobalide, a sesquiterpenoid lactone present in G. biloba, reportedly inhibits rat hippocampal 
NMDA-induced choline efflux after phospholipase A2 stimulation and membrane degeneration 
both in vitro and in vivo  studies (87). In a comparable investigation, hypoxia has also been 
shown to  release choline from rat hippocampal slices in a bilobalide reversible manner (88). 
Hence it might be hypothesized from the outcomes of such research, that bilobalide would have a 
potentially favorable action against the sequalae of hypoxia or excitotoxicity. 
G. biloba has proven to be a commonly employed herb for treating age-related memory loss and 
there are a number of reports on its  memory improving impact (89). The aging process is 
responsible for oxidative damage to DNA, protein, lipid, and other biological macromolecules. 
The resultant injury radically contributes to degenerative diseases occurring in the brain, sensory 
and cardiovascular systems. Substantial interest in the use of antioxidants has developed with an 
ultimate goal of protecting cellular components from oxyradical attack, especially 
lipoperoxidation (90). It has been revealed that acute treatment with G. biloba extract reduced 
α2-adrenoceptor binding density in the hippocampus and cerebral cortex of aged versus young 
rats. In contrast, chronic administration of Gingko extract actually elevated α2-adrenoceptor 
binding in aged animals, so it appears that noradrenergic activity in older rats is more prone to G. 
biloba exposure (91). Nonetheless, these findings should be considered in view of the extended 
Gingko enhancing effect on normetanephrine level, but also with the diminished cortical β-
adrenoceptor density plus adenylate cyclase activity mentioned earlier (83). 
Ovariectomy (OVX) in female rats combined with chronic stress restraint has been reported to 
create cognitive dysfunction along with hippocampal CA3 neuronal damage. Administration of 
Ginkgo biloba extract in these OVX/stressed animals improved both the memory impairment and 
hippocampal neuronal loss. Based on the outcome of this research work, it was speculated that 
Gingko had neuroprotective and cognitive enhancing properties at the postmenopausal stage of 
life (92). 
In humans, a clinical trial on G. biloba extract combined with risperidone in children aged 4-12 
years, did not disclose any change in treatment outcome on their ASD, although further studies 
were recommended in order to further validate the result (93). Nevertheless, in an earlier small 
observational study of 4-weeks duration, administration of G. biloba extract unveiled a degree 
of improvement in ADS symptoms (94) suggesting that the medicinal herb may have 
encouraging possibilities in this condition. 
 
 
 
CONCLUSION 
A rise in the incidence of autism in recent years may point to environmental risk variables (95) 
though environmental factors may interact with genetic vulnerabilities (96). Although the exact 
relationship  between autism and oxidative stress is not clear, different studies have shown that 
oxidative stress plays a key role in various diseases, especially those related to the nervous 
system (97). In individuals with ASD, numerous trials have already shown changes in 
antioxidants including catalase, glutathione peroxidase, and superoxide dismutase. In addition, 
modified concentrations of homocysteine/methionine and glutathione, as well as 
neuroinflammation, excitotoxicity, immune and mitochondrial dysfunction have been recorded 
in ASD. Genetic and environmental factors may intensify oxidative stress vulnerability (98) and 
a heightened oxidative stress status in autism may lead to exacerbation of the condition. In the 
context of this notion, all autism-effective medicinal crops possess conspicuous antioxidant 
activity which combined with anti-inflammatory activity and effects on neurotransmitters can be 
potential factors in ameliorating the symptoms of ASD. 
 
LIST OF ABBREVIATIONS  
AChEI  =   Acetylcholinesterase Inhibitor           
AD = Alzheimer’s disease  
APP = Amyloid Precursor Protein   
AA = Asiatic Acid  
ADHD = Attention Deficit Hyperactivity Disorder  
ASD = Autism spectrum disorder  
BDNF = Brain Derived Neurotrophic Factor  
BChE = Butyrylcholinesterase  
CREB = cAMP Response Element-Binding Protein  
COMT = Catechol-O-methyltransferase  
CA = Centella asiatica  
ETC = Electron Transport Chain  
Fmri = Functional Magnetic Resonance Imaging  
GABA = Gamma Amino Butyric Acid  
GAD = Glutamic Acid Decarboxylase  
GPX = Glutathione Peroxidase  
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IL = Interleukin  
LPS = Lipopolysaccharide  
MDA = Malondialdehyde  
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ROS = Reactive Oxygen Species  
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